Kite gets US FDA nod for Yescarta to treat relapsed or refractory follicular lymphoma
Yescarta is the first CAR T-Cell therapy approved for indolent follicular lymphoma
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.